trending Market Intelligence /marketintelligence/en/news-insights/trending/VZ1wzu0TjC_lpjuLssrOmw2 content esgSubNav
In This List

Generex Biotechnology shelves plan to buy majority stake in Core-Tech Solutions

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Generex Biotechnology shelves plan to buy majority stake in Core-Tech Solutions

Generex Biotechnology Corp. said it terminated a letter of intent to buy a controlling interest in privately held Core-Tech Solutions Inc.

The U.S.-based maker of drug delivery systems had signed a letter of intent in August to acquire a 51% interest in Core-Tech Solutions for $15 million.

Core-Tech Solutions is a contract-based maker of transdermal patches that are placed on the skin to deliver medication into the bloodstream.

Generex Biotechnology said two pharmaceutical companies, which had commercialization contracts with Core-Tech, will not proceed with three contract development programs in the Core-Tech pipeline due to the re-evaluation of their priorities.

The new development, which came up during a due diligence, modified cash-flow projections and the requisite cash support needed from Generex for product development of the Core-Tech pipeline.

This led Generex to re-examine Core-Tech's valuation, with both parties discussing a restructuring of the letter of intent before agreeing to shelve the talks.

While Core-Tech confirmed formal termination of the letter of intent Dec. 8, the companies may revisit the deal later.